Overview of Fetroja

Property	Description
Active ingredient	Cefiderocol
Form	Powder for solution
Pharmacological class	Siderophore Cephalosporin, \beta-lactam antibiotic
General use	Treating serious Gram-negative bacterial infections
Origin	Synthetic

Defining Cefiderocol: A Siderophore Cephalosporin

Cefiderocol is a prescription, synthetic antibacterial agent classified as a siderophore cephalosporin, a specialized type of \beta-lactam antibiotic. This \Delta^3-cephem derivative contains the active ingredient Cefiderocol sulfate, which functions by inhibiting the synthesis of the bacterial cell wall, a core mechanism inherent to the \beta-lactam class. Cefiderocol represents an advancement in antibiotic pharmacology, with its development being specifically targeted at the challenge of increasing antibiotic resistance.

The drug is internationally recognized, with the World Health Organization (WHO) classifying it in the Reserve Group of Antibiotics, a category emphasizing its importance for critical patient care when first-line options have failed. This positioning is consistent with its intended use as a vital therapeutic tool for patients facing complex bacterial threats.

Composition, Form, and General Purpose

The medicine is provided in a powder for solution form, which is intended for reconstitution prior to intravenous infusion only. The active ingredient, Cefiderocol sulfate, is the single component responsible for the antibacterial activity. This injectable formulation is administered exclusively in a clinical setting, distinguishing it from orally administered or topically applied antibiotics.

The general therapeutic purpose of this agent is to address serious infections caused by aerobic Gram-negative bacteria, particularly in instances where the bacteria have developed resistance mechanisms. Cefiderocol's unique structure allows it to employ a "Trojan Horse" strategy, utilizing the bacteria's natural iron transport systems to actively enter the cell. The compound is structurally designed to maintain activity against multi-drug resistant strains of Gram-negative bacteria.

Regulatory References

What side effects are possible with Fetroja?

Possible Side Effects and Safety Information

The safety profile of Fetroja (Cefiderocol) is formally documented in government regulatory labeling, categorizing potential effects by frequency and the body system affected. This information strictly outlines documented adverse reactions and contextual safety considerations, without providing any clinical advice or instructions for use.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to how often they have been reported in clinical studies:

Very Common (Affecting ge 1 in 10 people): Diarrhea and increases in hepatic transaminases (ALT and AST, indicators of liver function).
Common (Affecting ge 1 in 100 people): Hematologic changes such as anemia and thrombocytopenia (low platelet count); metabolic disturbances like hypokalemia (low potassium); infections including candidiasis and Clostridioides difficile colitis; nausea, vomiting, headache, and phlebitis at the infusion site.

Serious and Contextual Safety Information

Regulatory documentation highlights specific adverse reactions considered serious or clinically significant:

Serious Adverse Reactions: These include potentially severe hypersensitivity reactions (e.g., anaphylaxis), seizures and other central nervous system events, and severe Clostridioides difficile-associated diarrhea.
Population and Exposure Constraints: Caution is noted for patients with severe renal impairment, as this may increase drug exposure and raise the risk of CNS adverse reactions. Furthermore, the label includes a safety note regarding an observed imbalance in all-cause mortality in critically ill patients treated for infections other than complicated urinary tract infection or pneumonia.

The regulatory safety profile thus defines the official framework for understanding the medicine's risk, specifying both the expected, frequent reactions and the rare, serious events that must be considered within the authorized conditions of use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Cefiderocol (Fetroja) addresses overdose by describing the risks associated with excessive systemic concentrations, rather than specific unique symptoms. The European Medicines Agency notes that no information on clinical signs and symptoms directly associated with an overdose is available.

Documented Overexposure Manifestations

Overexposure, which can occur with an overdose, is linked to Central Nervous System (CNS) adverse reactions due to the drug's classification as a cephalosporin. These severe manifestations include seizures, encephalopathy, coma, and neuromuscular excitability, as noted in the U.S. Prescribing Information. Patients with pre-existing renal impairment or a history of epilepsy are specifically identified as being at increased risk for these severe CNS events when drug levels are excessive.

Required Emergency Actions

Immediate medical help is required if a severe reaction or any sign of CNS overexposure is observed. For patients exhibiting signs such as focal tremors or seizures, the official guidance mandates an immediate evaluation to determine if the medicine must be discontinued. There is no specific antidote for Cefiderocol overdose. Management is symptomatic and supportive, with hemodialysis listed as a specific procedural measure capable of removing the drug from the body.

Therapeutic Uses of Fetroja

Main Uses of Fetroja

Fetroja (cefiderocol) is an antibiotic used to treat serious bacterial infections in adults. It belongs to a class of medications known as siderophore cephalosporins. This medication is specifically utilized when infections are caused by certain types of Gram-negative bacteria that have developed resistance to other common antibiotics.

Conditions Treated

Fetroja is primarily used for the following medical conditions:

Urinary Tract Infections (UTI): This includes complicated urinary tract infections and kidney infections (pyelonephritis) that are difficult to treat with standard therapies.
Pneumonia: It is used for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), which are severe lung infections that occur during or after a hospital stay.

How it Works

Fetroja has a unique mechanism for entering bacterial cells. Many resistant bacteria create barriers to keep antibiotics out; however, Fetroja mimics the iron molecules that bacteria need to survive. The bacteria actively transport the medication across their outer membranes, allowing the antibiotic to bypass traditional resistance mechanisms and destroy the cell from within.

Benefits in Clinical Care

The primary benefit of Fetroja is its effectiveness against multidrug-resistant organisms. When standard antibiotics fail because bacteria have produced enzymes (such as carbapenemases) to neutralize them, Fetroja often remains active.

By providing a treatment option for infections that otherwise have limited or no remaining therapeutic alternatives, it serves as a critical tool in managing complex cases where bacterial resistance is a primary concern.

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Fetroja

Official regulatory documents define the population eligible for Fetroja (cefiderocol) based on age, allergy history, organ function, and the severity of the infection being treated.

Eligibility Scope

Classification	Status & Population	Constraint Details
Contraindicated	Patients with a known history of severe hypersensitivity to cefiderocol or to any other beta-lactam antibacterial drug (e.g., penicillins) are strictly prohibited from use.	Absolute prohibition based on allergic history
Age-Restricted	Use is indicated for patients 18 years of age or older (adults).	Safety and effectiveness have not been established in the pediatric population (under 18 years).
Conditional Use	Patients with impaired renal function or augmented renal clearance (high CrCL) are eligible, but use is conditional.	Requires dosage modification based on calculated Creatinine Clearance value.
Condition-Specific	Reserved for use only in patients who have limited or no alternative treatment options for the specific susceptible infection.	Use for certain severe, carbapenem-resistant infections is reserved due to an observed signal of increased mortality.

Pregnancy and Lactation

Pregnancy: Use is generally avoided unless the potential benefit justifies the potential risk to the fetus.
Lactation: A decision must be made to discontinue breastfeeding or to discontinue therapy while accounting for the benefit of the medicine to the mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cefiderocol (Fetroja) is primarily characterized by a pharmacokinetic interaction involving substances that modify renal clearance.

Documented Pharmacokinetic Interactions

Co-administration with Probenecid is officially documented as a drug-drug interaction. Probenecid is a known inhibitor of renal organic anion transporters (OATs), which are responsible for eliminating Cefiderocol from the body. This inhibition leads to reduced renal clearance of Cefiderocol, resulting in an increase in the drug’s systemic exposure (AUC) by approximately 35%.

Cefiderocol is not expected to participate in major metabolic interactions, as it is neither a substrate, inhibitor, nor inducer of the primary cytochrome P450 (CYP) isoenzymes (e.g., CYP1A2, CYP2C9, CYP3A4). This means that co-administration with other medicines metabolized by these pathways is generally not anticipated to result in clinically significant changes to their respective concentrations.

Interaction-Related Restrictions and Constraints

Category	Regulatory Status
Formal Contraindications	None documented. Official labeling does not list any specific medicinal products as contraindicated due to interaction risk.
Timing Requirements	None documented. No mandatory dose separation or timing rules are specified for co-administration.
Food/Substance Interaction	None documented. As an intravenous infusion product, there are no documented interactions with food, alcohol, or herbal products.

This profile is defined by the single, known transporter-mediated interaction and the explicit absence of major metabolic pathway or food interactions.

Mechanism of Action

The Mechanism of Cefiderocol

Cefiderocol employs a dual mechanism beginning with active transport across the bacterial outer membrane. The drug functions as a siderophore, binding to ferric iron (Fe^3+) and being actively transported into the periplasmic space via the bacterium's native iron-uptake systems (e.g., CirA and PiuA transporters). This entry mechanism contributes to a higher local drug concentration by utilizing the iron transport system instead of relying on non-functional porin channels or being affected by active efflux pumps.

Once in the periplasm, the beta-lactam core binds irreversibly to essential bacterial enzymes called Penicillin-Binding Proteins (PBPs), primarily PBP3. This inhibition blocks the final peptidoglycan cross-linking step in cell wall assembly. The resulting structural instability compromises the cell's integrity, leading to rupture via osmotic pressure and the production of a bactericidal effect. The drug's molecular structure also confers intrinsic stability against hydrolysis by major classes of beta-lactamase enzymes, allowing it to complete its core mechanistic cascade.

Dosage and Administration Information

Cefiderocol (Fetroja) is administered strictly as an intravenous (IV) infusion and is intended for use in a clinical setting. It is supplied as a powder for concentrate for solution for infusion, requiring a specific two-step process of reconstitution and subsequent dilution with an approved solution, such as 0.9% Sodium Chloride or 5% Dextrose, before it can be used.

The standardized regimen for adults with normal kidney function (Creatinine Clearance, CLcr, 60 to 119 mL/min) is 2 grams administered every 8 hours (q8h). However, the dosing schedule is directly governed by the patient's renal function, necessitating mandatory adjustments across the full spectrum of kidney function, including augmented clearance. For instance, patients with CLcr of 120 mL/min or greater receive 2 grams every 6 hours, while those on intermittent hemodialysis receive a lower dose of 0.75 grams every 12 hours, administered immediately after the dialysis session.

A crucial administration constraint is the requirement that each dose must be infused over a fixed 3-hour period, regardless of the patient’s renal function or the specific dose amount. Treatment typically follows a defined course, ranging from 7 to 14 days. This medicine should not be physically mixed or co-administered with other medicinal products in the same syringe or infusion solution. No dose adjustment is specified for older adults or patients with hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Fetroja

Evidence for Complicated Urinary Urinary Tract Infections (cUTI) and Pyelonephritis

Research exploring Cefiderocol for complicated urinary tract infections (cUTI), including kidney infections known as pyelonephritis, involved pivotal randomized controlled trials (RCTs) that compared Cefiderocol to an existing, active antibiotic treatment. The research examined the study's primary objective: the trial design used to measure the outcome relative to the active comparator. The study outcome measured was a composite outcome of both the microbiological clearance of bacteria from the urine and the patients' clinical status (symptom resolution) at a specific time point after treatment.

These short-term trials described patterns observed in patients receiving Cefiderocol when used in research exploring how symptoms change over time and in settings involving acute or disruptive symptom patterns. Follow-up was limited to short-term observation durations after treatment completion at the Test-of-Cure visit. Therefore, there is limited information for long-term outcomes regarding the durability of the microbiological clearance.

Evidence for Hospital-Acquired and Ventilator-Associated Pneumonia (HABP/VABP)

For severe lung infections acquired in the hospital setting, such as Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP), evidence is also derived from pivotal randomized controlled trials (RCTs). The studies evaluated the primary endpoint known as clinical cure, which involves monitoring the state of infection signs and symptoms, and also tracked all-cause mortality.

The studies focused on critically ill adults, including a significant portion of patients who were on mechanical ventilation. Long-term effects are not fully established for this patient group, as follow-up was focused on the short-term clinical status and 28- and 49-day mortality. Furthermore, comparative evidence is lacking for certain subgroups of critically ill patients, as the trial design compared it against an existing treatment.

Evidence for Infections Caused by Carbapenem-Resistant Gram-Negative Pathogens (CRGNPs)

For serious infections caused by Carbapenem-Resistant Gram-Negative Pathogens (CRGNPs)—bacteria that are difficult to treat—the main evaluation was observed in a randomized, open-label, descriptive Phase 3 study where Cefiderocol was studied for its use against a non-standardized Best Available Therapy (BAT) chosen by the physician.

Regulatory summaries indicate that this specific open-label study was associated with a higher all-cause mortality rate observed in the Cefiderocol group relative to the BAT group for certain infections, such as pneumonia and bloodstream infections. The specific reasons for this difference were not definitively determined in the study itself. Evidence is limited because sample sizes in this descriptive study were small due to the rarity of these infections.

Frequently Asked Questions (FAQ)

Common questions about Fetroja (FAQ)

Q: Does Fetroja interact with common over-the-counter pain medications like ibuprofen or acetaminophen?

Official drug interaction information indicates that Fetroja is not expected to cause major metabolic interactions with many other medicines. This is because it does not affect the function of key liver enzymes (CYP450) responsible for processing other drugs in the body. Interactions are typically evaluated by a healthcare professional based on a patient’s full medication history.

Q: What are the signs of an allergic reaction to Fetroja that require medical attention?

Official regulatory documents warn about the possibility of serious and potentially life-threatening hypersensitivity reactions, such as anaphylaxis. Signs to watch for include developing a rash or hives, severe itching, trouble breathing, or swelling of the face, hands, or mouth. The appearance of these signs is described in the label as an event that requires emergency medical evaluation.

Q: Is Fetroja used in elderly patients (e.g., over 65) and are there any special considerations?

Studies have not demonstrated that patients over 65 have different safety or effectiveness concerns compared to younger adults, so the medicine is used in this population. However, older patients are more likely to have age-related changes in kidney function. Because Fetroja is cleared by the kidneys, the dose must be carefully adjusted based on the patient's calculated kidney function as a required safety step.

Q: Does Fetroja have a Black Box Warning, and what does it address?

The U.S. FDA label includes a prominent Warning (sometimes called a 'Black Box Warning') regarding an observed increase in all-cause mortality. This finding was seen in studies involving patients treated with Fetroja for serious infections other than complicated urinary tract infection or hospital-acquired pneumonia. This mortality finding is included in the label to describe the safety context and ensure informed use.

Q: Is Fetroja effective against infections caused by Pseudomonas aeruginosa?

Yes, official indications state that Fetroja is used to treat infections caused by susceptible strains of Gram-negative bacteria, including Pseudomonas aeruginosa. The medicine is specifically intended for certain complicated infections where this organism is involved.

Q: What makes Fetroja different from an older antibiotic like Cefepime?

Fetroja is classified as a unique type of cephalosporin called a siderophore. The drug's structure enables it to use the bacteria's own iron transport system, sometimes referred to as a 'Trojan Horse' strategy, to enter the bacterial cell. This mechanism of entry allows the drug to overcome some of the resistance mechanisms that affect older cephalosporin antibiotics.

Q: What are the key findings or results from the primary clinical trials for Fetroja?

Regulatory documents summarize the clinical trials that supported the drug's approval. The studies demonstrated that Fetroja was able to meet its primary objectives, such as achieving non-inferiority in clinical and microbiological cure rates, when compared to other established, active antibiotics used as comparators. These results were confined to the approved indications, such as complicated urinary tract and certain severe lung infections.

Q: Is Fetroja considered a broad-spectrum antibiotic?

No. Official product information describes Fetroja as being primarily active against aerobic Gram-negative bacteria. It is not considered a traditional broad-spectrum antibiotic because it has no clinically relevant activity against most Gram-positive bacteria or anaerobic bacteria.

Q: Is Fetroja ever used in combination with other medicines?

While the medicine should not be physically mixed with other products in the same intravenous bag, official information does not specify restrictions on its systemic use in combination regimens. For example, some clinical trials designed to test Fetroja's safety and efficacy also provided patients with an initial coverage antibiotic for Gram-positive bacteria.

Q: Why do some patients experience diarrhea when taking Fetroja?

Diarrhea is listed in official documents as a common adverse reaction for Fetroja, as it is with many systemic antibiotics. Antibiotics can cause diarrhea by disturbing the natural balance of bacteria in the gut. The official label also includes a specific warning about the potential for developing a severe form of diarrhea called Clostridioides difficile-associated diarrhea (CDAD).

Q: How long has Fetroja been available since its initial regulatory approval?

Fetroja (cefiderocol) was first approved by the U.S. Food and Drug Administration (FDA) on November 14, 2019, for the treatment of complicated urinary tract infections. It has since been approved by other major international regulatory bodies.

Q: Does Fetroja carry a risk of interaction with oral contraceptives?

Official drug information does not list a specific interaction between Fetroja and oral contraceptives. However, due to its classification as a beta-lactam antibiotic, there is a general, theoretical possibility of decreased effectiveness for estrogen-containing contraceptives.

Q: What should be done for dry mouth or thirst while receiving Fetroja?

Dry mouth and increased thirst are adverse reactions that have been reported in clinical trials. The regulatory label does not include specific management instructions, but patients are generally advised to discuss any bothersome side effects with their healthcare professional.

Q: Does Fetroja cause problems with sleep or insomnia?

Insomnia, which is difficulty falling or staying asleep, is listed in the official safety documents as an adverse reaction that was reported by some patients during clinical trials. This is considered a less common side effect.

How should Fetroja be stored and disposed of?

Storage and Disposal Requirements for Fetroja

The storage of Fetroja (cefiderocol) is governed by strict regulatory conditions to ensure stability. Unopened vials of the powder for injection must be stored in a refrigerator at a temperature between 2 C and 8 C. To protect the powder from light, the vials must remain in their original carton until preparation.

Stability and Handling

Once reconstituted, the solution in the vial is stable for only 1 hour at room temperature. The final diluted solution is stable for a maximum of 6 hours at room temperature or up to 24 hours under refrigeration. The medicine must be kept out of the sight and reach of children.

Disposal

Any unused reconstituted product must be discarded. Disposal of the unused medicine and related waste must be performed in accordance with local regulations.

Fetroja